Published • loading... • Updated
V940 Plus Pembrolizumab Cuts Melanoma Recurrence Risk by 49%
Summary by cancernetwork.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.5 Articles
5 Articles
estrepublicain.fr+3 Reposted by 3 other sources
New encouraging results in melanoma. In patients operated with this skin cancer, combine a therapeutic vaccine with experimental RNA with a treatment that helps the immune system to better combat cancer, reduces the risk of recurrence and prolongs the period without re-emergence of the disease.
·Nancy, France
Read Full ArticleCoverage Details
Total News Sources5
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
